Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Travere Therapeutics (TVTX) Long-Term Investments (2018 - 2019)

Travere Therapeutics filings provide 3 years of Long-Term Investments readings, the most recent being $15.0 million for Q2 2019.

On a quarterly basis, Long-Term Investments changed 0.0% to $15.0 million in Q2 2019 year-over-year; TTM through Jun 2019 was $15.0 million, a 0.0% change, with the full-year FY2018 number at $15.0 million, changed N/A from a year prior.
Long-Term Investments hit $15.0 million in Q2 2019 for Travere Therapeutics, roughly flat from $15.0 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $15.0 million in Q1 2018 to a low of $15.0 million in Q1 2018.